An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma

Local Institution - 0045, Ghent

Local Institution - 0047, Sint-Niklaas

Local Institution - 0001, New York

Memorial Sloan Kettering Cancer Center, New York

Local Institution - 0039, Athens

Abramson Cancer Center, Philadelphia

Local Institution - 0007, Philadelphia

Fox Chase Cancer Center, Philadelphia

Local Institution - 0004, Philadelphia

Local Institution - 0003, Baltimore

The Sidney Kimmel Comprehensive Cancer Center, Baltimore

Local Institution - 0023, Orlando

Local Institution, Bologna

Local Institution - 0028, Columbus

Local Institution - 0044, Nantes

Local Institution - 0019, Indianapolis

Local Institution - 0011, Ann Arbor

University Of Michigan Health System, Ann Arbor

Local Institution - 0002, Rochester

Mayo Clinic, Rochester

Local Institution - 0037, Skokie

Local Institution - 0018, Westwood

Local Institution - 0033, Omaha

Local Institution - 0017, Aurora

Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City

Local Institution - 0005, Salt Lake City

Local Institution - 0043, Poitiers

Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles

Local Institution - 0012, Los Angeles

Local Institution - 0035, Clovis

Local Institution - 0006, Portland

OHSU Center for Hematologic Malignancies, Portland

Local Institution - 013, New Haven

Dana-Farber Cancer Institute, Boston

Local Institution - 0009, Boston

Local Institution - 0015, Boston

John Theurer Cancer Center, Hackensack

Local Institution - 0014, Hackensack

Local Institution, Yvoir

Local Institution, Chorzów

Local Institution - 0040, Poznan

Local Institution - 0049, Warsaw

Local Institution - 0042, Wroclaw